Name (Print/Type)

Signature

Mary K. VanAtten

U. S. Patient and Trademark Office: U.S. DEPARTMENT OF COMMENCE
U.S. Patient and Trademark Office: U.S. DEPARTMENT OF COMMENCE
Urder the Paperwork Reduction Act of 1995, no persone are required to respond to a collection of information urless of deligine; availed Office or more available of the Comment or available of the Comment o

## UTILITY PATENT APPLICATION TRANSMITTAL

Attorney Docket No. PH-7268 Prints Inventor Percy Carter et al

Title ACTIVITY

ACTIVITY

PROPRIEM

PH-7268

DIAMINES AS MODULATORS OF CHEMOKINE RECEPTOR OF CHEMOKINE RECEPTOR

Express Mail Label No EV000875494 US (Only for new nonprovisional applications under 37 C F.R. 1 53(b)) Assistant Commissioner for Patents APPLICATION ELEMENTS Box Patent Application Washington, DC 20231 ADDRESS TO: See MPEP chapter 600 concerning utility patent application contents 1. 🔯 7. CD-ROM or CD-R in duplicate, large table or Fee Transmittal Form (e.g., PTO/SB/17) (Submit an onginal and a dup Computer Program (Appendix) 2. 🗆 Applicant claims small entity status. 8. Nucleotide and/or Amino Acid Sequence Submission See 37 CFB 1.27. (if applicable, all necessary) з. 🔯 Specification [Total Pages a. Computer Readable Form (CRF) (preferred arrangement set forth below) b. Specification Sequence Listing on: i. CD-ROM or CD-R (2 copies); or ii. paper - Descriptive title of the Invention - Cross Reference to Related Applications Statement Regarding Fed sponsored R & D Statements verifying identity of above copies - Reference to sequence listing, a table or a computer program listing appendix - Background of the invention ACCOMPANYING APPLICATIONS PARTS - Brief Summary of the Invention 9. Assignment Papers (cover sheet & document(s)) - Brief Description of the Drawings ( if filed) 10. 🖂 37 C.F.R.§3.73(b) Statement Power of - Detailed Description (when there is an assignee) Attorney - Claim(s) - Abstract of the Disclosum 11. English Translation Document (if applicable) 4. Drawing(s) (35 U.S.C.113) [Total Sheets 12. 🗍 Information Disclosure Copies of IDS Statement (IDS)/PTO-1449 Citations Total Pages 1 5. Oath or Declaration 13. Preliminary Amendment a Newly executed (original or copy) 14. 🛛 Return Receipt Postcard (MPEP 503) b. Copy from a prior application (37 CFR 1.63 (d)) (Should be specifically itemized) (for a continuation/divisional with Box 18 completed) 15. 🗌 Certified Copy of Priority Document(s) i, DELETION OF INVENTOR(S) (if foreign priority is claimed) Signed statement attached deleting inventor(s) 16. 🖂 Nonoublication Request under 35 U.S.C. 122 named in the prior application, see 37 CFR (b)(2)(B)(i). Applicant must attach form PTO/SB/35 1 63(d)(2) and 1 33(b) or its equivalent. Application Data Sheet. See 37 CFR 1.76 17. Other: 18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or In an Application Data Sheet under 37 CFR 1.76: □ Divisional of prior application No: \_\_\_\_ □ Continuation Continuation-in-part (CIP) Prior application information. Examiner Group / Art Unit. For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying or divisional application and is hereby incorporated by reference.

The incorporation gan only be relied upon when a portion has been inadvertently omitted from the submitted application parts. 17. CORRESPONDENCE ADDRESS 24348 Customer Number or Bar Code Label Correspondence address below PATENT TRADEMARK OFFICE Name Address City State Zip Code Fax Country Telephone

Burden Hour Statement This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete his form should be sent to the Chair Information Officer, U.S. Patient and Trademark Officer, Washington, DC 2020 1.07 SEND FEES OR COMPLETED PORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patients, Sox-Patient Application, Washington, DC 2020 1.07 SEND POST COMPLETED PORTS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patients, Sox-Patient Application, Washington, DC 2020 1.07 SEND POST COMPLETED PORTS TO THE PAGE AND PROPERTY OF THE PAGE AND

Vans

Registration No. (Attorney/Agent)

39 408

20 December 2001

Date

Approved for use through 10/31/2002. OMB 6051/0025

Patent and Trademark Office U.S. Patent and Trademark Office U.S. Patent and Trademark Office U.S. OMB/PATTHENT OF COMMENCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless of stagings a valid DEMATCHENT OF COMMENCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless of stagings as valid DEMATCHENT OF COMMENCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless of stagings as valid DEMATCHENT OF COMMENCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless of the stagings as valid DEMATCHENT OF COMMENCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless of the stagings as valid DEMATCHENT OF COMMENCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless of the stagings as valid DEMATCHENT OF COMMENCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless of the staging as valid to the staging and the staging as valid to the stage of the sta

Attorney Docket No.

## **FEE TRANSMITTAL** for FY 2001

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT (S) 884.00

Complete if Known Unknown Application Number December 20, 2001 Filing Date First Named Inventor Percy Carter et al Examiner Name Unknown Group / Art Unit Unknown

PH-7268

THE PROPERTY OF THE PROPERTY O						The state of the s						
METHOD OF PAYMENT (check one)						FEE CALCULATION (continued) 3. ADDITIONAL FEES						
The Commissioner is hereby authorized to charge indicated fees and credit any over payments to:						ייטוווטע	IAL PE	:5				
1					Large Fee	Entity	Small Fee	Entity Fee		Fee		
⊠ Dep	osit				Code	(\$)	Code	(\$)	Fee Description	Paid		
Acco		023850		1	105	130	205	65	Surcharge - late filing fee or oath			
					127	50	227	25	Surcharge - late provisional filing fee or cover sheet.			
Deposit Account Bristol-Myers Squibb Pharma						130	139	130	Non-English specification			
Name Company					147	2.520	147	2,520	For filing a request for ex parte			
Charge Any Additional Fee Required									reexamination			
Under 37 CFR 1.16 and 1.17 Applicant claims small entity status.						820.	112	920*	Requesting publication of SIR pnor to Examiner action			
See 37 CFR 1 27 2. Payment Enclosed:						1,840*	113	1,840*	Requesting publication of SIR after Examiner action			
						110	215	55	Extension for reply within first month			
Check	☐ Cred		Order	her	116	400	216	195	Extension for reply within second month			
FEE CALCULATION						920	217	445	Extension for reply within third month			
BASIC FILING FEE					118	1,440	218	695	Extension for reply within fourth month			
Large Entity		ee Fee	Fee Description		128	1,960	228	945	Extension for reply within fifth month			
#		ode (\$)	rec bescription	Fee Paid	119	310	219	155	Notice of Appeal			
<b>1</b> 501	740 20	01 355	Utility filing fee	740	120	310	220	155	Filing a brief in support of an appeal			
106	330 20	06 160	Design filing fee		121	270	221	135	Request for oral hearing			
107 .±108		07 245 08 355	Plant filing fee Reissue filing fee		138	1,510	138	1,510	Petition to institute a public use proceeding			
114		14 75	Provisional filling fe		140	110	240	55	Petition to revive - unavoidable			
1.1	100 2	/5	TOVISIONE INNING I		141	1,240	241	620	Petition to revive - unintentional			
SUBTOTAL (1) (\$).740					142	1,240	242	620	Utility issue fee (or reissue)			
2. EXTRA CLAIM FEES					143	440	243	220	Design issue fee			
EXTHACLA	MIFEES		Extra Fee	from Fee	144	600	244	300	Plant issue fee			
±			Claims belo		122	130	122	130	Petitions to the Commissioner			
Potal Claims Independent Claims	28	-20**	8 X 1	= 144	123	130	123	50	Petitions related to provisional applications			
	1	-3**	• [ 0 ] × [	- 0	126	240	126	240	Submission of Information Disclosure Stmt			
Multiple Dependent Large Entit	/ Small	Entity	x 🗀	= 0	581	40	581	40	Recording each patent assignment per property (times number of			
		Fee Fe	e						properties)			
Fee Code 103	(\$)	Code (\$			146	710	246	355	Filing a submission after final rejection (37 CFR § 1.129(a))			
102		202 4		ims in excess of 3	149	710	249	355	For each additional invention to be			
104		204 13		ent claim, if not paid	-				maynined (37 CFR § 1 129(b))			
109	84	209 40	" Holasut Indo	vendent claims over	179 (RCE	710	27	9 355	Request for Continued Examination			
1			original patent		1							
110	18	210 9	over original par	ns in excess of 20 and ent	169	900	16	9 900	Request for expedited examination of a design application			
		SUBTO	TAL (2)	\$)144 00	1							
		005.0		(0) 147 00	la.					_		
						Other fee (specify)						
							*Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$)					
1					L							
"or number previo	rusty paid, if	greater: For R	elssues, see above									

Name (Pnnt/Type) Mary K. VanAtten Registration No. Attorney/Agent) 39,408 Telephone 302-695-6850 Van Atr 20 0

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

durusn Hour Statement. This form is essimated to take 0.2 flours or complete. Time will vary depending upon rise needs of time intrinsical ceses. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Relater and Trademark Officer, Washington, DC 20231.

ON OTHER STATE OF THE STATE OF TH